Recombinant Human DC protein

中文名： 脱氧胆酸(DC)牛血清白蛋白偶联物
别名： DC；D2LIC；LIC3；Cytoplasmic dynein 2 light intermediate chain 1

货号: PA2000-393DB

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	DC
Uniprot No	Q8TCX1
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-352aa
氨基酸序列	MPSETLWEIAKAEVEKRGINGSEGDGAEIAEKFVFFIGSKNGGKTTIILRCLDRDEPPKPTLALEYTYGRRAKGHNTPKDIAHFWELGGGTSLLDLISIPITGDTLRTFSLVLVLDLSKPNDLWPTMENLLQATKSHVDKVIMKLGKTNAKAVSEMRQKIWNNMPKDHPQDHELIDPFPVPLVIIGSKYDVFQDFESEKRKVICKTLRFVAHYYGASLMFTSKSEALLLKIRGVINQLAFGIDKSKSICVDQNKPLFITAGLDSFGQIGSPPVPENDIGKLHAHSPMELWKKVYEKLFPPKSINTLKDIKDPARDPQYAENEVDEMRIQKDLELEQYKRSSSKSWKQIELDS
预测分子量	44.8kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是3条关于树突状细胞(DC)与重组蛋白相关的文献摘要示例：

---

1. **文献名称**：*Enhancement of antigen-presenting ability of dendritic cells by recombinant protein transduction*

**作者**：Smith A, et al.

**摘要**：该研究探讨了利用重组蛋白(如gp100或HER2/neu)体外负载人源DC的策略，证明通过基因工程重组抗原可显著提升DC的抗原呈递效率，并诱导更强的肿瘤特异性CD8+ T细胞应答，为癌症疫苗开发提供新思路。

---

2. **文献名称**：*Targeted delivery of recombinant cytokines to dendritic cells via fusion proteins*

**作者**：Wang Y, et al.

**摘要**：研究者设计了一种重组融合蛋白(如GM-CSF/IL-4融合体)，通过靶向DC表面受体(如CD40或DEC205)，特异性促进DC的成熟与迁移。动物实验显示该策略可增强抗病毒免疫应答，降低传统细胞因子的全身毒性。

---

3. **文献名称**：*Recombinant viral vectors encoding tumor antigens prime dendritic cells for immunotherapy*

**作者**：Nchinda G, et al.

**摘要**：研究利用重组腺病毒载体将肿瘤相关抗原(如MUC1或PSA)递送至DC，证明其在体内外均能有效激活DC并引发多克隆T细胞反应，为基于DC的个性化肿瘤免疫治疗提供实验依据。

---

注：以上为模拟文献摘要，实际研究中需根据具体主题检索PubMed或Web of Science获取真实文献。如需进一步精确方向(如特定疾病或蛋白类型)，可补充说明调整内容。

背景信息

Dendritic cell (DC)-based recombinant proteins represent a promising frontier in immunotherapy and vaccine development, leveraging the innate role of DCs as professional antigen-presenting cells. DCs are central to adaptive immunity, bridging innate immune detection and targeted T-cell responses. By engineering these cells to express recombinant proteins—often tumor-associated antigens, viral epitopes, or immunomodulatory molecules—researchers aim to enhance their capacity to prime antigen-specific immune reactions.

The concept emerged in the 1990s as genetic engineering advanced, enabling precise antigen loading onto DCs. Early approaches involved pulsing DCs with peptides or mRNA encoding antigens. Recombinant protein technology later offered advantages, including improved stability, controlled antigen presentation, and the potential for multi-epitope incorporation. Modern strategies often involve fusing antigens with DC-targeting ligands (e.g., anti-DEC205 antibodies) or immune adjuvants (e.g., TLR agonists) to optimize uptake and activation.

Clinically, DC recombinant proteins have shown potential in cancer immunotherapy. Notable examples include Provenge (sipuleucel-T), an FDA-approved autologous DC therapy for prostate cancer, though newer recombinant platforms seek to overcome limitations like production complexity. Infectious disease applications focus on vaccines against HIV, influenza, and emerging pathogens, where DC-targeted recombinant proteins aim to elicit robust, durable immunity.

Challenges persist in achieving consistent DC activation, avoiding tolerance induction, and scaling manufacturing. Current research explores synergies with checkpoint inhibitors, personalized neoantigen platforms, and nanotechnology-enhanced delivery. As understanding of DC biology deepens, recombinant protein strategies continue evolving toward precision-engineered immunotherapies with broader clinical applicability.